GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lantheus Holdings Inc (NAS:LNTH) » Definitions » Cyclically Adjusted PS Ratio

LNTH (Lantheus Holdings) Cyclically Adjusted PS Ratio : 5.67 (As of May. 30, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Lantheus Holdings Cyclically Adjusted PS Ratio?

As of today (2025-05-30), Lantheus Holdings's current share price is $75.52. Lantheus Holdings's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was $13.33. Lantheus Holdings's Cyclically Adjusted PS Ratio for today is 5.67.

The historical rank and industry rank for Lantheus Holdings's Cyclically Adjusted PS Ratio or its related term are showing as below:

LNTH' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 3.99   Med: 6.06   Max: 9.36
Current: 5.63

During the past years, Lantheus Holdings's highest Cyclically Adjusted PS Ratio was 9.36. The lowest was 3.99. And the median was 6.06.

LNTH's Cyclically Adjusted PS Ratio is ranked worse than
81.14% of 737 companies
in the Drug Manufacturers industry
Industry Median: 2.12 vs LNTH: 5.63

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Lantheus Holdings's adjusted revenue per share data for the three months ended in Mar. 2025 was $5.216. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $13.33 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Lantheus Holdings Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Lantheus Holdings's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lantheus Holdings Cyclically Adjusted PS Ratio Chart

Lantheus Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 4.20 4.89 6.79

Lantheus Holdings Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.82 6.09 8.31 6.79 7.32

Competitive Comparison of Lantheus Holdings's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Lantheus Holdings's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lantheus Holdings's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lantheus Holdings's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Lantheus Holdings's Cyclically Adjusted PS Ratio falls into.


;
;

Lantheus Holdings Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Lantheus Holdings's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=75.52/13.33
=5.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lantheus Holdings's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Lantheus Holdings's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=5.216/134.9266*134.9266
=5.216

Current CPI (Mar. 2025) = 134.9266.

Lantheus Holdings Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 3.879 100.684 5.198
201509 2.410 100.392 3.239
201512 2.340 99.792 3.164
201603 2.518 100.470 3.382
201606 2.553 101.688 3.387
201609 2.255 101.861 2.987
201612 1.984 101.863 2.628
201703 2.108 102.862 2.765
201706 2.284 103.349 2.982
201709 2.043 104.136 2.647
201712 2.102 104.011 2.727
201803 2.092 105.290 2.681
201806 2.172 106.317 2.756
201809 2.256 106.507 2.858
201812 2.178 105.998 2.772
201903 2.174 107.251 2.735
201906 2.130 108.070 2.659
201909 2.129 108.329 2.652
201912 2.229 108.420 2.774
202003 2.262 108.902 2.803
202006 1.530 108.767 1.898
202009 1.325 109.815 1.628
202012 1.406 109.897 1.726
202103 1.366 111.754 1.649
202106 1.497 114.631 1.762
202109 1.509 115.734 1.759
202112 1.913 117.630 2.194
202203 2.982 121.301 3.317
202206 3.160 125.017 3.410
202209 3.367 125.227 3.628
202212 3.724 125.222 4.013
202303 4.440 127.348 4.704
202306 4.530 128.729 4.748
202309 4.568 129.860 4.746
202312 5.046 129.419 5.261
202403 5.278 131.776 5.404
202406 5.582 132.554 5.682
202409 5.184 133.029 5.258
202412 5.386 133.157 5.458
202503 5.216 134.927 5.216

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Lantheus Holdings  (NAS:LNTH) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Lantheus Holdings Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Lantheus Holdings's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Lantheus Holdings Business Description

Traded in Other Exchanges
Address
201 Burlington Road, South Building, Bedford, MA, USA, 01730
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
Executives
Marshall Robert J. Jr. officer: CFO and Treasurer C/O LANTHEUS MEDICAL IMAGING, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Mary Anne Heino director, officer: CEO and President C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA NY 01862
Paul Blanchfield officer: Chief Commercial Officer C/O LANTHEUS HOLDINGS, INC., 331, NORTH BILLERICA MA 01862
James H Thrall director 343 COMMERCIAL STREET #314, BOSTON MA 02109
Daniel Niedzwiecki officer: See Remarks C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Gerard Ber director C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Andrea Sabens officer: Chief Accounting Officer C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Gary J Pruden director ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Heinz Christoph Maeusli director SCHUETZENWEG 3, ENGELBURG V8 9032
Julie Mchugh director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Sam R Leno director C/O BOSTON SCIENTIFIC CORPORATION, ONE BOSTON SCIENTIFIC PLACE, NATICK MA 01760
Minnie Baylor-henry director C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803
Etienne Montagut officer: See Remarks C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Brian A Markison director 501 FIFTH STREET, BRISTOL TN 37620
Jean-claude Provost officer: Chief Medical Officer C/O LANTHEUS HOLDINGS, INC., 201 BURLINGTON RD, SOUTH BUILDING, BEDFORD MA 01730